OCUL
OCUL clinical trials: OCULAR THERAPEUTIX, INC
Every trial on ClinicalTrials.gov where OCULAR THERAPEUTIX, INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 58
- Trials linked
- 33
- As lead sponsor
- 25
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
OCUL on the catalyst calendar · OCUL registry changes
- Primary completion May 28, 2024ActualPhase 1NCT05695417Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative...Ocular Therapeutix, Inc. · Non-proliferative Diabetic RetinopathyCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 24, 2024ActualPhase 2NCT05335122A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or...Ocular Therapeutix, Inc. · Open Angle GlaucomaCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2030Sponsor estimatePhase 3NCT07516132Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular...Ocular Therapeutix, Inc. · Neovascular Age-Related Macular Degeneration (nAMD)RecruitingOCULLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 3NCT07235085A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyOcular Therapeutix, Inc. · Non-Proliferative Diabetic RetinopathyRecruitingOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 8, 2027Sponsor estimatePhase 3NCT06495918Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular...Ocular Therapeutix, Inc. · Neovascular Age-related Macular DegenerationActive, not recruitingOCULLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2026Sponsor estimatePhase 3NCT06223958Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular...Ocular Therapeutix, Inc. · Neovascular Age-Related Macular DegenerationActive, not recruitingOCULLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2021ActualPhase 1NCT04360174CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular HypertensionOcular Therapeutix, Inc. · Ocular HypertensionCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 22, 2024ActualPhase 2NCT05814757OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)Ocular Therapeutix, Inc. · Dry Eye SyndromesCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 10, 2024ActualPhase 1NCT03630315CLN-0046: Treatment of AMD Subjects With OTX-TKIOcular Therapeutix, Inc. · Neovascular Age-related Macular DegenerationCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 21, 2023ActualPhase 3NCT04539548A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric...Ocular Therapeutix, Inc. · CataractCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 6, 2023ActualPhase 1NCT04989699Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular DegenerationOcular Therapeutix, Inc. · Neovascular Age-Related Macular DegenerationCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2021ActualPhase 1/Phase 2NCT04362670Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.Ocular Therapeutix, Inc. · Dry Eye DiseaseCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2020ActualPhase 3NCT04061044A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular InsertOcular Therapeutix, Inc. · Open Angle Glaucoma and Ocular HypertensionCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2022ActualEarly Phase 1NCT04945824A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy SubjectsOcular Therapeutix, Inc. · HealthyTerminatedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 11, 2021ActualPhase 2NCT04747977To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye DiseaseOcular Therapeutix, Inc. · Dry EyeCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2023Sponsor estimateNo phase registeredNCT05307081An Observational, Qualitative Study Assessing Eye Drop AdministrationOcular Therapeutix, Inc. · Ocular InjuryUnknown statusOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2013ActualPhase 2NCT01666210Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract SurgeryOcular Therapeutix, Inc. · Ocular Inflammation and PainCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2009ActualNo phase registeredNCT00774228I-ZIP Ocular Bandage Pivotal StudyOcular Therapeutix, Inc. · CataractCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2019ActualPhase 3NCT02914509Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHTOcular Therapeutix, Inc. · Open Angle GlaucomaCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2020ActualPhase 3NCT04050865A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic ConjunctivitisOcular Therapeutix, Inc. · Allergic ConjunctivitisCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2016ActualPhase 3NCT02988882OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic ConjunctivitisOcular Therapeutix, Inc. · Chronic Allergic ConjunctivitisCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2020Sponsor estimateNo phase registeredNCT02309736OTX-14-002: Device Exposure RegistryOcular Therapeutix, Inc. · EndophthalmitisWithdrawnOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 3NCT02034019Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract SurgeryOcular Therapeutix, Inc. · Post Ocular Surgical Inflammation and PainCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2015ActualPhase 3NCT02089113OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After...Ocular Therapeutix, Inc. · Post-Surgical Ocular PainCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 2NCT02062905OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic ConjunctivitisOcular Therapeutix, Inc. · Chronic Allergic ConjunctivitisCompletedOCULLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 33 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner